PUBLISHER: The Business Research Company | PRODUCT CODE: 1815760
PUBLISHER: The Business Research Company | PRODUCT CODE: 1815760
Cell banking outsourcing involves contracting external organizations to establish, maintain, and manage repositories of cell lines critical for various applications in the biotechnology and pharmaceutical industries, such as drug discovery and biomanufacturing. This practice ensures that cells are handled, stored, and maintained under standardized conditions, guaranteeing consistency and reliability.
The primary types of cell banking outsourcing encompass master cell banking, working cell banking, and viral cell banking. Master cell banking (MCB) entails a repository of well-characterized cells derived from a single clone, intended to serve as the foundational material for producing therapeutic products such as biologics or cell therapies. This includes various types of cells such as stem cell banking and non-stem cell banking, involving phases such as bank storage, bank characterization and testing, and bank preparation.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.
The cell banking outsourcing market research report is one of a series of new reports from The Business Research Company that provides cell banking outsourcing market statistics, including cell banking outsourcing industry global market size, regional shares, competitors with a cell banking outsourcing market share, detailed cell banking outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the cell banking outsourcing industry. This cell banking outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cell banking outsourcing market size has grown rapidly in recent years. It will grow from $11.19 billion in 2024 to $12.86 billion in 2025 at a compound annual growth rate (CAGR) of 15.0%. The growth in the historic period can be attributed to the rise in the prevalence of chronic diseases, the increased number of government initiatives, regulatory support and guidelines, and the increase in the establishment of banking services.
The cell banking outsourcing market size is expected to see rapid growth in the next few years. It will grow to $21.65 billion in 2029 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to rising adoption of cellular products, growing demand for monoclonal antibodies, increasing adoption of stem cell therapies, rising geriatric population, and growing dependency on cell-based therapies. Major trends in the forecast period include product innovations, technological advancements, investments in research and development, and the collaboration between biotech companies and specialized cell banking services.
The forecast of 13.9% growth over the next five years reflects a modest reduction of 0.9% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. biopharma companies by driving up costs of cell banking services outsourced to China and India, exacerbating manufacturing startup expenses and increasing biologics development timelines. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising prevalence of chronic diseases is anticipated to drive the growth of the cell banking outsourcing market in the coming years. Chronic diseases, which are long-lasting conditions that develop gradually and endure over extended periods, are becoming more common due to factors such as lifestyle changes, aging populations, and genetic predispositions. Cell banking outsourcing plays a vital role in advancing research and development efforts to combat chronic diseases by providing access to expertise, resources, and infrastructure that may not be readily available in-house. For example, in April 2022, a report from the National Association of Chronic Disease Directors (NACDD), a U.S.-based non-profit public health organization focused on chronic disease programs, indicated that nearly 60% of American adults have at least one chronic disease, and about 40% have multiple chronic conditions (MCC). This is projected to cost the U.S. economy $2 trillion annually, or approximately $8,600 per person, by 2030. Thus, the increasing burden of chronic diseases is driving growth in the cell banking outsourcing market.
Prominent companies in the cell banking outsourcing market are dedicated to developing technologically advanced solutions, such as single-cell potency characterization platforms, to deliver precise and comprehensive analysis of individual cell potency. A single-cell potency characterization platform comprises sophisticated technologies or methodologies tailored to evaluate and quantify the potency and functional capabilities of individual cells within a cell population. For instance, in January 2024, Cellply Srl, an Italy-based biotechnology company, introduced VivaCyte, its flagship product and an end-to-end single-cell potency characterization platform. VivaCyte integrates potency analysis and immunophenotyping to streamline cell therapy research and development. This fully automated, standalone platform with single-cell resolution aims to expedite development timelines, reduce costs, and mitigate risks by swiftly characterizing the intricate functionality and mechanism of action of potential cellular immunotherapies. It enables rapid testing of multiple cell therapy candidates against various target tumor cells, providing reproducible immune cell characterization and single-cell functional assessment in a fraction of the time required by conventional analytical tools.
In July 2022, KCAS Bioanalytical & Biomarker Services, a US-based provider of comprehensive bioanalytical services, acquired FlowMetric LLC for an undisclosed sum. Through this acquisition, KCAS intends to bolster its capabilities in supporting cell and gene therapy programs and meet the escalating demands of its clientele by offering additional operational support to effectively address the burgeoning industry needs. FlowMetric LLC, a US-based biotechnology company, specializes in pre-clinical services such as cell sorting, functional analysis of cell signaling, and cell banking outsourcing.
Major companies operating in the cell banking outsourcing market are Labcorp Drug Development, SGS Life Sciences, Lonza Group Ltd., WuXi AppTec, Charles River Laboratories, Sigma-Aldrich Co. Ltd., Covance Inc., Global Stem Inc., LifeCell, Cryoviva India, Sartorius AG, Bio Reliance, CordLife, Reliance Life Sciences, Cryo-Cell International Inc., Toxikon Corp., Cleancells, Clean Biologics, Texcell, PX'Therapeutics SA, Goodwin Biotechnology Inc., Transcell Biolife Pvt Ltd, Perfectus Biomed Limited, BioStorage Technologies Inc.
North America was the largest region in the cell banking outsourcing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell banking outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the cell banking outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The cell banking outsourcing market includes revenues earned by entities by providing services, such as cell line establishment, cryopreservation, cell line characterization, facilitating the distribution of cell lines, and quality control. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cell Banking Outsourcing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on cell banking outsourcing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for cell banking outsourcing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cell banking outsourcing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.